Bortezomib 3.5 mg
| Product Overview | |
| Generic Name | Bortezomib 3.5 mg |
| Brand Name(s) | Biosimilar |
| Form | Lyophilized powder/injection (IV or SC). |
| Strength | 3.5 mg |
| Therapeutic Class | Antineoplastic (proteasome inhibitor) |
| ATC Code | L01XG01 |
| Manufacturing & Regulatory | |
| Manufacturer | Ellia |
| Country | Mexico, India |
| GMP Compliance | WHO–GMP |
| DMF/CEP | Type II |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 100 units |
| Shelf Life | 36 months |
| Storage | 2–8 °C, protect from light |
| Incoterms | Ex-Mexico |
| Lead Time | 7 to 10 days |
| Documentation | |
| Certificate of Analysis (COA) | Yes—lot-specific Certificate of Analysis |
| SDS | Available upon request from manufacturer/distributor |
| CTD Summary | CTD available to regulators; summary available to qualified partners |
Description
Indicateds & Usage; in relapsed and untreated multiple myeloma and untreated mantle cell lymphoma.
